Scott M Fields

US Patent:

20040186127, Sep 23, 2004

Filed:

Jan 7, 2004

Appl. No.:

10/753261

Inventors:

Jane Daun - Dracut MA, US
Scott Fields - Towaco NJ, US
Seiichi Kobayashi - Belmont MA, US

Assignee:

Eisai Co., Ltd. - Tokyo

International Classification:

C07D471/02
A61K031/4745

US Classification:

514/303000, 546/119000

Abstract:

The present invention provides methods of using compounds having formula (I): wherein R, R, Rand n are as described generally and in classes and subclasses herein, in the treatment of reperfusion injuries, osteoporosis and/or bone metastasis.

US Patent:

20140065100, Mar 6, 2014

Filed:

Nov 8, 2013

Appl. No.:

14/075130

Inventors:

- Tokyo, JP
Sally T. Ishizaka - Weston MA, US
Lynn D. Hawkins - Andover MA, US
Scott Fields - Towaco NJ, US

Assignee:

Eisai R&D Management Co., Ltd. - Tokyo

International Classification:

A61K 39/00
A61K 45/06

US Classification:

424 852, 4242771, 4242041, 4242271, 4242281, 4242301, 4242291, 4241331, 4241311, 424 851

Abstract:

The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.

US Patent:

20230106592, Apr 6, 2023

Filed:

Aug 18, 2022

Appl. No.:

17/820773

Inventors:

- Boston MA, US
Peter LITTLEWOOD - Abingdon, GB
Philip Michael REAPER - Abingdon, GB
Mohammed ASMAL - Newton MA, US
Scott Zachary FIELDS - Towaco NJ, US

International Classification:

A61K 31/497
A61K 45/06
A61K 31/7068
A61K 31/4965
A61K 31/555
A61K 31/519
A61K 33/243
A61P 35/00
A61K 31/282
A61N 5/10

Abstract:

Described herein are methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a DNA damaging agent and between about 12 and about 48 hours later administering to the subject a compound that inhibits ATR protein kinase. Methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a compound that inhibits ATR protein kinase are also described. Exemplary ATR inhibitors are represented by Formulae A-I and A-II:or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.

US Patent:

20180303829, Oct 25, 2018

Filed:

Sep 30, 2016

Appl. No.:

15/763366

Inventors:

- Boston MA, US
Peter LITTLEWOOD - Abingdon, Oxfordshire, GB
Philip Michael REAPER - Abingdon, Oxfordshire, GB
Mohammed ASMAL - Newton MA, US
Scott Zachary FIELDS - Towaco NJ, US

International Classification:

A61K 31/497
A61K 45/06
A61K 33/24
A61K 31/7068
A61K 31/282
A61P 35/00
A61N 5/10

Abstract:

Described herein are methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a DNA damaging agent and between about 12 and about 48 hours later administering to the subject a compound that inhibits ATR protein kinase. Methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a compound that inhibits ATR protein kinase are also described. Exemplary ATR inhibitors are represented by Formulae A-I and A-II or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.